| Source: CGL-CS |
| Type: |
| Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death). MAPK Pathways: The MAPK family includes several pathways, the most notable being: 1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival. 2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis. 3.p38 MAPK: Associated with inflammatory responses and apoptosis. Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations. Altered Expression Levels: Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival. Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling. The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers. Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion. |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| - | NA, | NA, | Jurkat | - | NA, | NA, | HL-60 | - | NA, | NA, | RAW264.7 |
| 7565- | HYP, | Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review |
| - | Review, | AD, | NA |
| 7548- | HYP, | Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation |
| - | in-vitro, | NSCLC, | A549 |
| 7554- | HYP, | Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism |
| - | in-vitro, | NSCLC, | A549 |
| 7385- | IBC, | Fighting cancer by triggering non-canonical mitochondrial permeability transition-driven necrosis through reactive oxygen species induction |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | 4T1 |
| 7635- | Ins, | The Role of Inositols in Endocrine and Neuroendocrine Tumors |
| - | Review, | Thyroid, | NA |
| 7747- | ISL, | Isoliquiritigenin Induces Apoptosis via ROS-Mediated Inhibition of p38/mTOR/STAT3 Pathway in Human Melanoma Cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 7758- | ISL, | Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications |
| - | Review, | Ovarian, | NA |
| 7862- | isoO, | Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia |
| - | in-vitro, | Nor, | BV2 |
| 7853- | isoO, | Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review |
| - | Review, | Var, | NA |
| 7873- | isoO, | Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Lung, | A549 |
| 7872- | isoO, | Isoorientin ameliorates H2O2-induced apoptosis and oxidative stress in chondrocytes by regulating MAPK and PI3K/Akt pathways |
| - | in-vivo, | Arthritis, | NA |
| 7812- | ISQ, | Isoquercitrin promotes ferroptosis and oxidative stress in nasopharyngeal carcinoma via the AMPK/NF-κB pathway |
| - | vitro+vivo, | NPC, | CNE1 | - | in-vitro, | NPC, | HNE1 |
| 8040- | IVM, | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
| - | Review, | Var, | NA |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
| 7900- | IVT, | Isovitexin: A Promising Active Compound Found in Nature's Bounty |
| - | in-vivo, | Nor, | NA |
| 7888- | IVT, | Isovitexin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways |
| - | vitro+vivo, | Nor, | NA |
| 5118- | JG, | Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 5099- | JG, | Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK |
| - | vitro+vivo, | GBM, | LN229 | - | vitro+vivo, | GBM, | T98G |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| - | Review, | Nor, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
| 8056- | KAE, | Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
| 8242- | LCA, | Nrf2 signaling and autophagy are complementary in protecting lipopolysaccharide/d-galactosamine-induced acute liver injury by licochalcone A |
| - | in-vivo, | LiverDam, | NA |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8230- | LCA, | The Ameliorative Role of Lico A on Aflatoxin B1-Triggered Hepatotoxicity Partially by Activating Nrf2 Signal Pathway |
| - | vitro+vivo, | Nor, | NA |
| 8206- | LCA, | Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways |
| - | in-vivo, | GC, | BGC-823 |
| 8229- | LCA, | Licochalcone A: a review of its pharmacology activities and molecular mechanisms |
| - | Review, | Nor, | NA |
| 8130- | LF, | Lactoferrin targeting INTL1 receptor inhibits hepatocellular carcinoma progression via apoptosis and cell cycle signaling pathways |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HepG3 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8135- | LF, | Lactoferrin-A Regulator of Iron Homeostasis and Its Implications in Cancer |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8144- | LF, | A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway |
| - | Human, | AD, | NA |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3528- | Lyco, | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3266- | Lyco, | Effects of lycopene on number and function of human peripheral blood endothelial progenitor cells cultivated with high glucose |
| - | in-vitro, | Nor, | NA |
| 1714- | Lyco, | Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load |
| - | in-vitro, | Ovarian, | OV-MZ-6 | - | in-vivo, | NA, | NA |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 2533- | M-Blu, | PDT, | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 6540- | MeSal, | Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK |
| - | in-vitro, | CRC, | HCT116 |
| 2243- | MF, | Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study |
| - | in-vitro, | Nor, | NA |
| 3457- | MF, | Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis |
| - | Review, | Var, | NA |
| 3477- | MF, | Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:181 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid